MIBDX Performance — BNY Mellon Bond Fund, Investor Shares
Data updated: 2026-07-31
MIBDX returned +0.18% year to date and +4.59% over one year to May 2026. Annualised returns are +3.49% over 3 years and −0.36% over 5 years. The fund trailed its Intermediate Core Bond category average: $100 invested three years ago grew to $111, against $115 for the category, and to $105 over one year, against $105. Volatility over the past three years was 5.71% a year. In the 12 months to May 2026 the fund lost a net $47.7M, and assets reached $1.19B.
MIBDX Growth of $100
What $100 invested in BNY Mellon Bond Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Intermediate Core Bond category average over the same months.
| Period | MIBDX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $105 | $105 |
| 3 years (Jun 2023 – May 2026) | $111 | $115 |
| 5 years (Jun 2021 – May 2026) | $98 | $103 |
| Since data start (Sep 2019 – May 2026) | $103 | $109 |
MIBDX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +0.18% |
| 1 year | +4.59% |
| 3 years (annualised) | +3.49% |
| 5 years (annualised) | −0.36% |
MIBDX Annual Returns
Calendar-year total returns of BNY Mellon Bond Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +0.18% |
| 2025 | +6.96% |
| 2024 | +0.75% |
| 2023 | +5.22% |
| 2022 | −13.77% |
| 2021 | −1.71% |
| 2020 | +7.59% |
| 2019 (Sep–Dec) | −0.40% |
MIBDX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.2% | +1.6% | −1.9% | +0.1% | +0.3% | — | — | — | — | — | — | — |
| 2025 | +0.5% | +2.3% | −0.1% | +0.3% | −0.6% | +1.5% | −0.2% | +1.2% | +1.0% | +0.6% | +0.5% | −0.3% |
| 2024 | −0.1% | −1.5% | +0.9% | −2.7% | +1.8% | +0.8% | +2.4% | +1.4% | +1.3% | −2.7% | +1.1% | −1.9% |
| 2023 | +3.3% | −2.4% | +2.3% | +0.6% | −1.1% | −0.3% | −0.1% | −0.7% | −2.5% | −1.7% | +4.6% | +3.7% |
| 2022 | −2.3% | −1.4% | −2.8% | −3.8% | +0.4% | −1.8% | +2.3% | −2.6% | −4.3% | −1.2% | +3.6% | −0.6% |
| 2021 | −0.4% | −1.4% | −1.1% | +0.8% | +0.1% | +0.7% | +0.9% | −0.3% | −0.8% | −0.2% | +0.1% | −0.2% |
| 2020 | +2.1% | +1.4% | −1.8% | +1.9% | +0.9% | +1.1% | +1.7% | −0.6% | −0.1% | −0.6% | +1.4% | +0.3% |
| 2019 | — | — | — | — | — | — | — | — | −0.7% | +0.3% | 0.0% | 0.0% |
MIBDX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 5.71%
- 3-year Sharpe ratio: -0.18 (vs 4.5% risk-free rate)
- Best month: +4.57% (Nov 2023)
- Worst month: −2.67% (Apr 2024)
MIBDX Fund Flows
Monthly money in and out of BNY Mellon Bond Fund, from SEC Form N-PORT.
- 12-month net flow: −$47.7M
- 12-month gross sales (incl. reinvestments): $249.7M
- Sales ÷ redemptions: 0.84×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $33.6M | $13.3M | $20.3M |
| Apr 2026 | $13.9M | $11.8M | $2.1M |
| Mar 2026 | $16.8M | $27.1M | −$10.3M |
| Feb 2026 | $17.1M | $18.0M | −$936K |
| Jan 2026 | $11.5M | $21.1M | −$9.6M |
| Dec 2025 | $15.7M | $19.1M | −$3.4M |
| Nov 2025 | $14.4M | $24.3M | −$9.9M |
| Oct 2025 | $12.3M | $43.2M | −$30.9M |
| Sep 2025 | $23.5M | $46.5M | −$23.0M |
| Aug 2025 | $34.1M | $11.1M | $23.0M |
| Jul 2025 | $24.0M | $19.0M | $5.0M |
| Jun 2025 | $32.8M | $42.9M | −$10.1M |
MIBDX Assets Under Management
Net assets of BNY Mellon Bond Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $1.19B |
| 2026-02-28 | $1.21B |
| 2025-11-30 | $1.21B |
| 2025-08-31 | $1.26B |
| 2025-05-31 | $1.22B |
| 2025-02-28 | $1.30B |
| 2024-11-30 | $1.35B |
| 2024-08-31 | $1.28B |
| 2024-05-31 | $1.18B |
| 2024-02-29 | $1.22B |
| 2023-11-30 | $1.19B |
| 2023-08-31 | $1.19B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.